DOCSLIB.ORG

Subject Index

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Subject Index Subject Index absorption enhancer 166 bile acid Ill; 160 (see also permeability enhancer) binary complexes 74 acetaminophen 61, 128, 138, 143,214 bioavailability 105, 108, 145, 153, 156, 166, (see also paracetamol) 169,173,174,177,181-183 acetic acid 75 biopharmaceutics 105 acetohexaminde 119 biphenyl 73 acetone 74, 85 biphenyl acetate 169, 175, 176,208 acetylsalicylic acid 65, 66, 95,154,200 biphenyl acetic acid 169, 121 acid hydrolysis 12 biphenylacetic ester 200 adenosinediphosphate 123 bisabolol 66 adhesive tapes 187,211,212 bitter taste 127 adiabatic compressibility 6 (see also taste, unpleasant) aerosols 188 branched CDs 3, 44,157 alfaxalone 162 brexin 218 Allidex 218 bromo-benzene 48, 73 amantadine 54 buccal absorption 155 amino acids 134 buserelin acetate 183, 193,203 amorphous state 146 butylparaben 171 Amphotericin B 13,61,66 amylase 33 caboxymethylethyl-~CO 192 androsterone 42 caffeine 128 anethol129 camomile oil 89, 103, 130,213 aniline 53, 73, 74 camphor 129, 174, 186,209,213 anthracene 73 canrenone 68, 108 aroma 129 caproic acid 73 ascaridol 66, 76 capsules 155, 197,214 ascorbic acid 128,78 caraway oil 95 aspartame 128, 155 carbamazepine 119, 161 association constant 56 carbenicillin 66 atorpine 65 carbon dioxide 85 azulenol213 carmufor 66, 79, 114, 175, 192 Carthamus tinctorius 133 bandages 187,212 carvone68 barbiturate 34,117,124 catalytic effects 152 bead polymers 188 cataplasms 187,212 beclomethasone 119, 168 COPS 22, 41 bencyclane 128 COPS! 22,41 benexate 117 cephaeline 66, 70,157,202 benoxaprofen 69,123 cetylpyridinium bromide 188 benzaldehyde 117, 133, 155,200 cetylpyridinium-chloride 192 benzalkonium chloride 147, 160, 181 CGT-enzyme 14 benzene 48, 73 chamazulene 130 benzoate 74 chaulmoogric acid 76 benzocaine 65 chemically modified CDs 19 benzoic acid 48, 49, 54 chewing gum 132, 186 betamethason 66, 167, 168,203 chlorambucil 163 220 SUBJECT INDEX chloramphenicol 138, 145 199,202,207 chlorbutanol 174 dibucaine 205 chlorine 85 diclofenac 181 chloro-benzene 48, 73 diethyl ether 73,84 chlorophenol 73 differential scanning calorimetry 88 chlorpromazine 66, 70, 122, 124 diffusion 10,61,80 cholecalciferol 65, 78, 117 diffusion constaat 6 cholesterol 20, 41, 113, 122, 123, 124, 160 digitoxin 23, 24, 65, 66, 198 Cicladol218 digoxin 198 cimetidine 65 dihydroxypropyl derivatives 20 cinnarizine 66,110 diltiazem 66, 189, 190, 192,214 circular dichroism 58 DIMEB 20, 22, 25, 41, 43,70, 165 citral130 Dimethyl-aniline 73 c1obethasone 181,211 dimethylformamide 87 clofibrate 69, 128, 133, 153, 198 diphenhydramine 205 clumping tendency 88, 97 diphenylamine 13 cocrystallization 97 dipiridamole 22,28,29, 117, 123 competitive reactions 1l0, 113, 147, 167, 173, disintegration 135, 141, 144, 153, 154 177 disopyramide 128 complex preparation 83 dispersed amount method 99 compression of tablets 139 dissociation constant 52, 60, 146 congo red 57 dissolution properties 99 contact angle 99 dissolution rate 105, 139, 141, 145, 153, 154 corticosteroid 204 distribution of drugs 113 cortisol 42 doxorubicin 66 cortisone 135 drying 89 cosmetic emulsion 207 drying loss 5 cosmetics 159 creosote 128 effervescent tablets 155 critical micelle concentration 60 elimination of drugs 113 crosslinking agents 29 emetine 70,157,202 crown ether 73 emulsions 159,206,207 crushing strength 135, 136, 139 epichlorhydrin 29 crystal forms 6, 7 ergocalciferol 135, 137,202 crystal growth 158, 167, 173 essential oils 68,85,89, 129, 133, 173,208 crystal hydrage 74 estradiol 155, 163, 171, 172, 180, 183, 184, crystal lattice 5 185,208 crystallinity 135 ethambutol 65 crystal structure 74, 105, 139 ethano175,84,85,87 Crystal violet 57 ethiazide 66 crystal water 6 ethyl biphenyl acetate 175,208 CfG-ase enzyme 217 ethyl bromide 73 cyclodextrin hydrate 7 ethyl-<x-chlorophenoxyisobutyrate 148 cyclodextrinase enzymes 33 ethylene 85 cyclohexane 73 etoposide 66, 163 cyclosporin 181, 182 eucalyptus oil 174, 186,209 cymene 69,73 evolved gas analysis 93 eye drops 180, 181,210, 211 decane 14 eye lotions 170 density 135 eye ointments 170, 171 dermal preparations 165,203 detoxification 124 Falignost 154 dexamethasone 161, 186 fatty acid 48, 76, 94, 96, 128, 133, 166 dialysis 9, 124 fatty aicohol169, 191 dialyzing solution 165 femoxetine 128, 158,202 diazepam 23, 87, Ill, 140, 143, 177, 178, fendiline 90, 93 SUBJECT INDEX 221 fennel oil 209 interleukin 163 flavours 129, 217 intramuscular administration 164 flowing properties 88, 97 intravenous administration 163, 164 fluidity 136 iodine 15,74, 187 fluocinolone acetonide 187 iodoaniline 74 fluorescence 58 iodobenzene 48, 73 fluoro-benzene 48, 73 iodobenzoic acids 48 fluorometholone 181, 210 iomeglamic acid 154, 198 fluorouracil 79, 121 ipecac syrup 70, 157 flurbiprofen 24, 109, 113, 121, 164, 178, 180, ipriflavone 10 1, 109 181 IR spectroscopy 94 foam 206 irradiation 69, 71,123 fragrances 94 irritation 40, 42, 43, 120, 124, 164 free radical 70 isoleucine III friability 144 isomorphism 96 furosemide 66, 116, 141, 144, 145, 155 isosorbide dinitrate 66, 102, 187, 190, 191, 212 garlic oil 128, 133, 155,218 isosorbide-5-mononitrate 132 gels 105, 106, 167, 168 granulation 138, 140, 152 kneading method 86, 97 grinding 135, 154 krypton 74,85 griseofulvin 22, 28, 135, 145 growth hormone 163 lavender 103 guaiazulene 66, 130 lemon oil 69 leucine 111 haemolysis 20, 41, 43,69,120,122,123,164 libexine 128 haemolytic 42 lidocain 28,181, 191, 203, 210 hardness 144 linoleic acid 76 heparin 191 liposomes 159 hexamethylmelamine 163 liquid preparations 157 hexobarbital 114 liquid substances 133 hormones 182 lomustine 163 HP13CD 21, 22, 41, 42,136,147,165 lymphotropic transport 115 hydrocortisone 25, 28, 29, 87, 100, 102, 143, lysozyme 181 205 hydrolysis 37, 64 malachite green 57 hydroxyalkylated CDs 21 marcaine (bupivacaine) 192 hydroxybenzoic acid 60 marjoram 103 hydroxypropyl-CDs 27 mass spectrometry 88 hygroscopicity 97 mechanochemical activation 87 medroxyprogesterone acetate 199 ibuprofen 22,28, 100, 109, 145, 177, 179,207 mefenamic acid 190, 214 imipramine 123 mefenorex 65, 67 implants 159 melphalan 65, 66, 67 inclusion catalysis 63 melting point 8, 146 incompatibility 134, 166 membrane interactions 112, 120 indicators 57 menadione 59, 72, 78,105,117,134 indomethacin 22, 23, 28, 61, 66, 87, 101, 119, menatetrenone 197 121, 135, 138, 145, 154, 157, 171, 175, menthol 86, 90, 92, 129, 132, 186,209,213 181,190,197,207,211,214 mephalan 163 infusions 159 methanol 74, 75, 85 inhalants 186 methotrexate 163 injections 159 methyl-ethyl ketone 14,74 inorganic compounds 146 methyl orange 57, 72, 144 insulin 163, 164, 184,208 methyl-p-hydroxybenzoate 145 interactions, avoidance of 134 methylaniline 73 222 SUBJECT INDEX methylated CDs 25 penetration enhancer 171 methylene blue 57, 61 penicillin 187, 192 methylpentinol 96 pentobarbital 114 methyl salicylate 187 peppermint oil 132, 213,186 methyltestosterone 28 peptides 183 metoclopramid 191 percutaneous drug absorption 169, 171 metronidazole 66, 79, 158 periodate oxidation II miconazol167, 168, 169,205 peritoneal solution 165 micro-enemas III permeability enhancer 171 microcapsules 187 (see also absorption enhancer) Mitomycin C 66 permeability of membrane 112 mixing 135 pessaries 179 mixture 111, 113, 153, 161, 175, 179 pharmacokinetic parameters 109 mono palmi tin 89 pharmacokinetics 105, 114, 163, 164 morphine 119, 174 pharmacological effects 115 mydeton 66, 133 phase transfer 63 phenobarbital 105, 114, 117, 134, 139, 145, naphthalene 58, 73 175,199 naphthol 14, 74 phenol 53, 60, 147 naphthylamine 73 phenolphthalein 57 naproxen 112,113,121, 179, 191 phenylalanine 32, 110 nasal delivery 183,208 phenylbutazone 121 natural flavours 94 phenytoin 114,158,161,178 neohesperidin dihydrocha1cone 128 phospholipids 113, 159 nephrosis 38 photoallergic responses 123 neutral red 57 photodegradation 68 nicotinic acid 60 photolysis 68 nifedipine 101, 145 photooxidation 69 nitroglycerin 66, 96, 132, 133, 154, 187, 189, pinacyanol chloride 61 201,212,214 pinaverium bromide 128 nitrophenol49, 60, 61 piretanide 191, 215 nitrophenolate 74 piroxicam 109, 117, 119, 121, 138,217,218 nitrosamines 65 pirprofen 128 nitrosation 65 plant extracts 94 nitroxymethyl-6-chloropyridine 169, 187,212 polymers of cyclodextrins 114, 140, 155, 172, Nocloprost 133, 153 186,187,205,206 nonylic acid 187 polymorphic transition 89 nose drops 208, 210 polypeptides 163 nystatin 109, 181 powders 188,213 prednisolone 23, 24, 139, 145, 153, 164, 169, Oenanthera aquatica 134 177,178,199,204,207,211 odours 127 pregnadiene-dione 206, 210, 211 ointments 166, 203-205 preservati ve 152 ophthalmic preparations 180,210 prochlorperazine 124 orange oil 68, 130, 133 progesterone 24, 25, 138, 155, 184,210 ovine growth hormone 163 propanol 74, 75,85 oxidation 69 proscillaridin 64, 66 oxygen uptake 103, 130 prostacyclin 66 prostaglandin 65, 66, 77, 84, 133, 153, 160, papaverine 134 164, 174, 187, 189, 197, 201, 203, 211, paracetamol 89, 190,200 213 (see also acetaminophen) Prostarmon ® 77, 218 parenteral preparations 159 Prostavasin ® 77, 218 partial molar volumes 6 protein 146, 163 particle size 105, 135 protriptyline 69, 123 partition coefficient 63,166,171 pyrenesulphonate 72 SUBJECT INDEX 223 pyrolysis 88 surfactants 161, 166 pyrolytic gas chromatography 93 suspensions 157, 202 sustained release formulations 188,212-214 quinine 128 sweetness 127 syrups 201 RAMEB 20, 22, 25 rectal drug absorption 111 tablet hardness 135 rectal preparations 172, 184, 207 tablets 139, 154, 198,213,215 Rhodamine B 61 T AS technique 91 relative permittivity 6 taste, unpleasant 127,
Load more

Recommended publications
  • Pp375-430-Annex 1.Qxd
    ANNEX 1 CHEMICAL AND PHYSICAL DATA ON COMPOUNDS USED IN COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES AND HORMONAL MENOPAUSAL THERAPY Annex 1 describes the chemical and physical data, technical products, trends in produc- tion by region and uses of estrogens and progestogens in combined estrogen–progestogen contraceptives and hormonal menopausal therapy. Estrogens and progestogens are listed separately in alphabetical order. Trade names for these compounds alone and in combination are given in Annexes 2–4. Sales are listed according to the regions designated by WHO. These are: Africa: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia and Zimbabwe America (North): Canada, Central America (Antigua and Barbuda, Bahamas, Barbados, Belize, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago), United States of America America (South): Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guyana, Paraguay,
    [Show full text]
  • Canine Vascular Tissues Are Targets for Androgens, Estrogens, Progestins, and Glucocorticoids
    Canine vascular tissues are targets for androgens, estrogens, progestins, and glucocorticoids. K B Horwitz, L D Horwitz J Clin Invest. 1982;69(4):750-758. https://doi.org/10.1172/JCI110513. Research Article Sex differences and steroid hormones are known to influence the vascular system as shown by the different incidence of atherosclerosis in men and premenopausal women, or by the increased risk of cardiovascular diseases in women taking birth control pills or men taking estrogens. However, the mechanisms for these effects in vascular tissues are not known. Since steroid actions in target tissues are mediated by receptors, we have looked for cytoplasmic steroid receptor proteins in vascular tissues of dogs. We find specific saturable receptors, sedimenting at 8S on sucrose density gradients for estrogens (measured with [3H]estradiol +/- unlabeled diethylstilbestrol), androgens (measured with [3H]R1881 +/- unlabeled R1881 and triamcinolone acetonide), and glucocorticoids (measured with [3H]dexamethasone +/- unlabeled dexamethasone); they are absent for progesterone (measured with [3H]R5020 +/- unlabeled R5020 and dihydrotestosterone). Progesterone receptors can, however, be induced by 1-wk treatment of dogs with physiological estradiol concentrations (100 pg/ml serum estrogen), indicating a functional estrogen receptor. Receptor levels range from 20 to 2,000 fmol/mg DNA. They are specific for each hormone; unrelated steroids fail to complete for binding. Low dissociation constants, measured by Scatchard analyses, show that binding is of high affinity. Steroid binding sites are in the media and/or adventitia since they persist when the intima is removed. Compared with the arteries, receptor levels are reduced 80% in inferior venae cavae of […] Find the latest version: https://jci.me/110513/pdf Canine Vascular Tissues Are Targets for Androgens, Estrogens, Progestins, and Glucocorticoids KATHRYN B.
    [Show full text]
  • Chlormadinone Acetate As a Possible Effective Agent for Congenital Adrenal Hyperplasia to Suppress Elevated ACTH and Antagonize Masculinization
    Endocrine Journal 1995, 42(4), 505-508 Chlormadinone Acetate as a Possible Effective Agent for Congenital Adrenal Hyperplasia to Suppress Elevated ACTH and Antagonize Masculinization YUKIo KAGEYAMA, SATOSHIKITAHARA, TETSUROTSUKAMOTO, TOsHIHIKOTSUJII, SYUITIGOTO ANDHIROYUKI OSHIMA Department of Urology, Tokyo Medical and Dental University School of Medicine, Tokyo 113, Japan Abstract. We report two cases of congenital adrenal hyperplasia (CAH) in which administration of chlormadinone acetate (CMA), a substituted progestational agent for prostatic disease, suppressed ACTH hypersecretion and lowered plasma testosterone levels. Case 1 was 83-year-old male with advanced prostatic carcinoma and CAH due to 21-hydroxylase deficiency. His plasma testosterone did not decrease in spite of a bilateral orchiectomy. Case 2 was 40-year-old female with CAH due to 21- hydroxylase deficiency suffering from virilization after the cessation of cortisol supplement therapy because of her breast carcinoma. In these two cases, 'ral administration of CMA at a daily dose of 75- 100 mg suppressed ACTH and cortisol to subnormal levels and reduced testosterone levels. With the suppressive effect on ACTH excess and antiandrogenic action, CMA may be suitable for patients with CAH suffering from symptoms due to overproduced ACTH or adrenal androgen. Key words: Chlormadinone acetate , Congenital adrenal hyperplasia, ACTH suppression (Endocrine Journal 42: 505-508,1995) CHLORMADINONE acetate (17u-acetoxy-6-chlo- adrenal hyperplasia (CAH). Chlormadinone ace- ro-4,6-pregnadiene-3,20-dione; CMA), a substituted tate, administered for the prostatic carcinoma, progestational agent, has been used in the treat- suppressed hypersecretion of ACTH and lowered ment of benign prostatic hyperplasia (BPH) and plasma testosterone levels. With this experience prostatic carcinoma because of its anti-androgenic in mind, we administered CMA to a female pa- properties.
    [Show full text]
  • Combined Estrogen–Progestogen Menopausal Therapy
    COMBINED ESTROGEN–PROGESTOGEN MENOPAUSAL THERAPY Combined estrogen–progestogen menopausal therapy was considered by previous IARC Working Groups in 1998 and 2005 (IARC, 1999, 2007). Since that time, new data have become available, these have been incorporated into the Monograph, and taken into consideration in the present evaluation. 1. Exposure Data 1.1.2 Progestogens (a) Chlormadinone acetate Combined estrogen–progestogen meno- Chem. Abstr. Serv. Reg. No.: 302-22-7 pausal therapy involves the co-administration Chem. Abstr. Name: 17-(Acetyloxy)-6-chlo- of an estrogen and a progestogen to peri- or ropregna-4,6-diene-3,20-dione menopausal women. The use of estrogens with IUPAC Systematic Name: 6-Chloro-17-hy- progestogens has been recommended to prevent droxypregna-4,6-diene-3,20-dione, acetate the estrogen-associated risk of endometrial Synonyms: 17α-Acetoxy-6-chloro-4,6- cancer. Evidence from the Women’s Health pregnadiene-3,20-dione; 6-chloro-Δ6-17- Initiative (WHI) of adverse effects from the use acetoxyprogesterone; 6-chloro-Δ6-[17α] of a continuous combined estrogen–progestogen acetoxyprogesterone has affected prescribing. Patterns of exposure Structural and molecular formulae, and relative are also changing rapidly as the use of hormonal molecular mass therapy declines, the indications are restricted, O CH and the duration of the therapy is reduced (IARC, 3 C 2007). CH3 CH3 O C 1.1 Identification of the agents CH3 H O 1.1.1 Estrogens HH For Estrogens, see the Monograph on O Estrogen-only Menopausal Therapy in this Cl volume. C23H29ClO4 Relative molecular mass: 404.9 249 IARC MONOGRAPHS – 100A (b) Cyproterone acetate Structural and molecular formulae, and relative Chem.
    [Show full text]
  • Effects of Anti-Androgen, Tzp-4238 and Chlormadinone Acetate on the Adrenal Cortex -Histo- Pathological and Immunocyto- Chemical Studies
    ACTA HISTOCHEM. CYTOCHEM. Vol. 27, No. 4, pp. 365-372, 1994 EFFECTS OF ANTI-ANDROGEN, TZP-4238 AND CHLORMADINONE ACETATE ON THE ADRENAL CORTEX -HISTO- PATHOLOGICAL AND IMMUNOCYTO- CHEMICAL STUDIES- MASANORI MURAKOSHI, RIE INADA, MASASHI TAGAWA, KAZUHIRO IIZUKA, SHUUJI MASUDA, MINORU SUZUKI, ATSUSHI MIZOKAMI* AND KEIICHI WATANABE ** Safety Research Department, Teikoku Hormone Mfg. Co. Ltd., 1604 Shimosakunobe, Takatsu-ku, Kawasaki 213, *Department of Molecular Cell Biology, University of Occupational and Environmental Health, Kitakyushu 806 and **Department of Pathology, Tokai University School of Medicine, Bohseidai, Isehara-city, Kanagawa 259-11 Received for publication May 12, 1994, in revised form July 22, 1994 and re-revised form August 24, 1994 The atrophic effects of two synthetic steroidal anti-androgens, chlormadinone acetate (CMA) and TZP-4238, on the adrenal gland of rats were investigated by histopathological and immunocytochemical procedures. Male Sprague-Dawley rats were divided into four experimental groups. Group 1 consisted of intact controls. Groups 2 and 3 received TZP-423810 mg/kg/day and CMA 50 mg/kg/day p.o., respective- ly, for 3 weeks. Group 4 received distilled water containing 2% Tween 80 instead of TZP-4238 or CMA. CMA caused marked atrophy of the adrenal gland. Histopathologically, the remarkable atrophy was observed in the adrenal cortical cells of zonae fasciculata and reticularis. Intracellular localization of glutathione-peroxidase (GSH-PO) which effectively reduces the lipid peroxides, was mainly observed in the cytoplasmic matrix (cytosol GSH-PO) near the mitochondria or lipid droplets. In ddition, immunoreactivi- ty of intramitochondrial GSH-PO (mitochondrial GSH-PO) was less than that in the controls.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0161324 A1 Johansen Et Al
    US 2008O161324A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0161324 A1 Johansen et al. (43) Pub. Date: Jul. 3, 2008 (54) COMPOSITIONS AND METHODS FOR Publication Classification TREATMENT OF VRAL DISEASES (51) Int. Cl. (76) Inventors: Lisa M. Johansen, Belmont, MA A63/495 (2006.01) (US); Christopher M. Owens, A63L/35 (2006.01) Cambridge, MA (US); Christina CI2O I/68 (2006.01) Mawhinney, Jamaica Plain, MA A63L/404 (2006.01) (US); Todd W. Chappell, Boston, A63L/35 (2006.01) MA (US); Alexander T. Brown, A63/4965 (2006.01) Watertown, MA (US); Michael G. A6II 3L/21 (2006.01) Frank, Boston, MA (US); Ralf A6IP3L/20 (2006.01) Altmeyer, Singapore (SG) (52) U.S. Cl. ........ 514/255.03: 514/647; 435/6: 514/415; Correspondence Address: 514/460, 514/275: 514/529 CLARK & ELBNG LLP 101 FEDERAL STREET BOSTON, MA 02110 (57) ABSTRACT (21) Appl. No.: 11/900,893 The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain (22) Filed: Sep. 13, 2007 embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particu Related U.S. Application Data lar embodiments, the viral disease is viral hepatitis (e.g., (60) Provisional application No. 60/844,463, filed on Sep. hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E). 14, 2006, provisional application No. 60/874.061, Also featured are screening methods for identification of filed on Dec. 11, 2006. novel compounds that may be used to treat a viral disease.
    [Show full text]
  • Chlormadinone Acetate
    Chlormadinone Acetate sc-211070 Material Safety Data Sheet Hazard Alert Code EXTREME HIGH MODERATE LOW Key: Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION PRODUCT NAME Chlormadinone Acetate STATEMENT OF HAZARDOUS NATURE CONSIDERED A HAZARDOUS SUBSTANCE ACCORDING TO OSHA 29 CFR 1910.1200. NFPA FLAMMABILITY1 HEALTH0 HAZARD INSTABILITY0 SUPPLIER Santa Cruz Biotechnology, Inc. 2145 Delaware Avenue Santa Cruz, California 95060 800.457.3801 or 831.457.3800 EMERGENCY ChemWatch Within the US & Canada: 877-715-9305 Outside the US & Canada: +800 2436 2255 (1-800-CHEMCALL) or call +613 9573 3112 SYNONYMS C23-H29-Cl-O4, 17-acetoxy-6-chloro-6-dehydroprogesterone, 17alpha-acetoxy-6-chloro-6-dehydroprogesterone, "17alpha-acetoxy-6-chloro-6, 7-dehydroprogesterone", "17alpha-acetoxy-6-chloro-4, 6-pregnadiene-3, 20-dione", "17alpha-acetoxy-6-chloropregna-4, 6-diene-3, 20-dione", "17-(acetyloxy)-6-chloropregna-4, 6-diene-3, 20-dione", "6-chloro-17alpha-acetoxy-4, 6-pregnadiene-3, 20-dione", "delta(sup 6)-6-chloro-17alpha-acetoxyprogesterone", "6-chloro-delta(sup 6)-17-acetoxyprogesterone", "6-chloro-delta(sup 6)-(17alpha)acetoxyprogesterone", "6-chloro- delta(sup 6)-dehydro-17-acetoxyprogesterone", 6-chloro-6-dehydro-17alpha-acetoxyprogesterone, "6-chloro- 6-dehydro-17-alpha-hydroxyprogesterone acetate", "6-chloro-17-alpha-hydroxypregna-4, 6-diene-3, 20-dione acetate", "6-chloro-17-alpha-hydroxy-delta(sup 6)-progesterone acetate", "6-chloro-delta(sup 4, 6)-pregnadiene- 17-alpha-ol-3, 20-dione-17-", acetate, "6-chloro-pregna-4, 6-dien-17-alpha-ol-3,
    [Show full text]
  • Customs Tariff - Schedule Xxi - 1
    CUSTOMS TARIFF - SCHEDULE XXI - 1 Section XXI WORKS OF ART, COLLECTORS' PIECES AND ANTIQUES Issued January 1, 2013 CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2013 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT: Free Artificial bait; Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Crystallographic and Spectroscopic Study on a Known Orally Active Progestin
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by AIR Universita degli studi di Milano Accepted Manuscript Crystallographic and spectroscopic study on a known orally active progestin Patrizia Ferraboschi, Pierangela Ciuffreda, Samuele Ciceri, Paride Grisenti, Carlo Castellano, Fiorella Meneghetti PII: S0039-128X(15)00246-9 DOI: http://dx.doi.org/10.1016/j.steroids.2015.09.007 Reference: STE 7841 To appear in: Steroids Received Date: 24 April 2015 Revised Date: 10 August 2015 Accepted Date: 27 September 2015 Please cite this article as: Ferraboschi, P., Ciuffreda, P., Ciceri, S., Grisenti, P., Castellano, C., Meneghetti, F., Crystallographic and spectroscopic study on a known orally active progestin, Steroids (2015), doi: http://dx.doi.org/ 10.1016/j.steroids.2015.09.007 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Crystallographic and spectroscopic study on a known orally active progestin Patrizia Ferraboschi,a,* Pierangela Ciuffreda,b Samuele Ciceri,a Paride Grisenti,c Carlo Castellano,d and Fiorella Meneghettie aDipartimento di Biotecnologie Mediche e Medicina Traslazionale, Università degli Studi di Milano, Via Saldini 50, 20133 Milano, Italy bDipartimento di Scienze Biomediche e Cliniche “Luigi Sacco”, Università degli Studi di Milano, Via G.B.
    [Show full text]
  • Action of a Novel Nonsteroidal Antiandrogen, AA560 KEIZO
    Endocrinol. Japon. 1980, 27 (1), 69-76 Action of a Novel Nonsteroidal Antiandrogen, AA560 KEIZO SHIDA1, HIDETOSHI YAMANAKA1, ATSUSHI KOYA1, KATSUMIWAKABAYASHI2, HIROSHIMORI3, KENYU SHIBATA3 ANDEIICHIRO SHIMAZAWA3 1D epartment of Urology School of Medicine, Gunma University, Maebashi, 'Hormone Assay Center, Institute of Endocrinology, Gunma University, Maebashi, 3Research Division, Teikoku Hormone Mfg. Co., Kawasaki Synopsis The antiandrogenic properties of a new nonsteroidal antiandrogens, AA560 (N- (2-chloromethyl-2-hydroxypropionyl)-3, 4, 5-trichloroaniline) were investigated. The ventral prostate, dorselateral prostate and coagulating gland weights in rats given AA560 at1-9mg/head were significantly less than those in the intact rats. The seminal vesicle weights in rats given3-9mg/head were significantly less than those of the intact group. In intact animals given daily3or9mg of AA560there were significantly increases of serum FSH, LH and testosterone concentrations. In the in vivo experiment, the pretreatment with AA560decreased the uptake of 3H-androgens in the nuclear fraction of the ventral prostate. On the other hand, a significant increase in the uptake of3H-radioactivity in the cytosol fraction was observed. It was proved by the in vitro displacement study that AA560inhibited the binding of5a-dihydrotestosterone with a receptor protein in the prostatic cytosol. An intensive effort has been directed the transfer of5a-DHT into nucleus (Belham toward the research of antiandrogens because and Neal, 1971; Mangan and Mainwaring, of usefulness of these druge in a variety of 1972). On the other hand, SK&F7690was endocrinological disorders including hirsu- reported to inhibit the cytosol receptor bin- tism, acne, male pattern baldness, benign ding to5a-DHT and the rate of 5a-DHT prostatic hypertrophy and prostatic cancer.
    [Show full text]
  • Progestins and Rat Liver : an in Vitro Study of Binding Patricia Church Brown Yale University
    Yale University EliScholar – A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 1980 Progestins and rat liver : an in vitro study of binding Patricia Church Brown Yale University Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl Recommended Citation Brown, Patricia Church, "Progestins and rat liver : an in vitro study of binding" (1980). Yale Medicine Thesis Digital Library. 2425. http://elischolar.library.yale.edu/ymtdl/2425 This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more information, please contact [email protected]. YALE MEDICAL LIBRARY 3 9002 08627 9206 J Digitized by the Internet Archive in 2017 with funding from The National Endowment for the Humanities and the Arcadia Fund https://archive.org/details/progestinsratlivOObrow PROGESTINS AND RAT LIVER: An In Vitro Study of Binding Patricia Church Brown A Thesis Submitted to the Yale University School of Medicine in Partial Fulfillment of the Requirements for the Degree of Doctor of Medicine 1980 \\od- Lib ACKNOWLEDGEMENTS I would like to acknowledge my gratitude to the following individuals: Dr. Arnold J. Eisenfeld for his patience and constructive guidance during the preparation of this thesis. This project has introduced me to some of the methods of thought of investigative science, an introduction that should be of benefit in my future career.
    [Show full text]
  • Growth Inhibition and Increase of Insulin Receptors in Antiestrogen-Resistant T47dcohuman Breast Cancer Cells by Progestins: Implications for Endocrine Therapies1
    [CANCER RESEARCH 45,167-173, January 1985] Growth Inhibition and Increase of Insulin Receptors in Antiestrogen-resistant T47DCOHuman Breast Cancer Cells by Progestins: Implications for Endocrine Therapies1 Kathryn B. Horwitz2 and Gary R. Freidenberg3 Departments oíMedicine and Biochemistry, Biophysics, and Genetics, University of Colorado Health Sciences Center, Denver, Colorado 80262 ABSTRACT and the duration of remissions ranges from several months to 1 year or more (1, 25, 31, 33, 39, 43, 45). These results are There is renewed interest in the use of progestins to treat comparable to those obtained with antiestrogens, the most advanced breast cancer because results with these agents are common drug used for endocrine therapy (16, 39, 44). It is not comparable to those obtained with antiestrogens. However, it is known whether progestins act directly on the regressing tumors not known whether progestins inhibit the growth of breast tumor or indirectly through other hormones, (b) In support of the cells directly and independently of estradici. To study this, we hypothesis of Horwitz et al. (20), presence of PR4 may be the have used T47Dco human breast cancer cells. The progesterone single best marker for predicting both the hormone dependence receptors in these cells do not require estrogen induction, and of tumors and the disease-free survival of patients (11, 35). This this permits study of pure progestin effects without interference has led to speculation that PR-rich tumors would be especially by estradiol. We report here that, in the absence of estradici, sensitive to progestin treatment (26). (c) In small series of studies, physiological concentrations of progestins directly inhibit prolif positive responses to progestins have been obtained in tumors eration of these cells.
    [Show full text]